AlTi Global Inc. Makes New $384,000 Investment in Zoetis Inc. (NYSE:ZTS)

AlTi Global Inc. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,317 shares of the company's stock, valued at approximately $384,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after purchasing an additional 120,158 shares during the period. Geode Capital Management LLC increased its stake in Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after buying an additional 190,137 shares during the period. Polen Capital Management LLC raised its position in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after buying an additional 1,116,541 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Zoetis by 13.3% in the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after acquiring an additional 755,893 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company's stock.

Zoetis Stock Up 4.2 %

Shares of ZTS stock traded up $6.28 during trading on Wednesday, hitting $156.15. 4,453,847 shares of the company were exchanged, compared to its average volume of 2,479,023. The business's 50-day simple moving average is $157.64 and its 200 day simple moving average is $166.61. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market capitalization of $69.67 billion, a price-to-earnings ratio of 28.55, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the business posted $1.38 EPS. The company's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. Zoetis's payout ratio is 36.56%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Stifel Nicolaus cut their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Finally, Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $213.56.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.